Ask Warren

Seegene

096530 · KOSDAQ · ₩096530 · 씨젠

₩32,800▼ ₩750 (2.24%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y +25.67%
Market cap
₩1.5T
Enterprise value
₩1T
P/E
19.1×
P/B
1.5×
Dividend yield
3.0%
ROE
7.7%
Net margin
15.7%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−18.9% from the high

₩21,700Today: ₩32,350 – ₩33,950₩40,450

Returns

  • 1W−11.1%
  • 1M−3.5%
  • 3M+25.2%
  • 6M+32.3%
  • YTD+37.8%
  • 1Y+25.7%
Volume today
261,863
0.8× the 20-day average
Traded today
₩8.7B
Listed shares
46,734,402
EPS (12 months)
₩1,715
Earnings yield 5.2%
SellBuy
AI research · InitiationSeegene: Profitability Rebuilds From Losses as Shares Rise Toward 52-Week HighThe filed numbers show a clear improvement: a return to profit, a 12.1% trailing operating margin, strong cash generation and a low-debt balance sheet.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

39Quiet
  • BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
  • MomentumFlat-4.1% over the last month; the price is below its 20-day average.
  • News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 27: buy ₩530M at the close (4.5% of 20-day average trading value)

Sep 28Last 20 trading days (% of average trading value)Oct 27

On its 17 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 19.5% of trading value and pointed the same way 11 of 17 times.

  • 2× KODEX KOSDAQ150 Leverage ₩432M
  • 2× TIGER KOSDAQ150 Leverage ₩52M
  • -1× KODEX KOSDAQ150 Futures Inverse ₩30M
  • 2× RISE KOSDAQ150 Futures Leverage ₩9M
  • 2× KIWOOM KOSDAQ150 Futures Leverage ₩2.3M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 32,550

Basis −0.76% · implied rate −17.5%

Open interest 4,495 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

Seegene stock overview

Seegene (씨젠, KRX: 096530) is listed on KOSDAQ, in the Biotech & Pharma sector. Seegene is a Korean company founded in September 2000 that focuses on molecular diagnostics, detecting disease causes by analyzing DNA and RNA from human and animal samples. Its shares closed at ₩32,800 on Oct 27, 2026, down 2.24% on the day, giving it a market value of ₩1.5T.

Key facts

Market cap
₩1.5T
Sector
Biotech & Pharma
Latest price change
−2.24%
As of
Oct 27, 2026
Main business
Seegene is a Korean company founded in September 2000 that focuses on molecular diagnostics, detecting disease causes by analyzing DNA and RNA from human and animal samples.

Quick answers about Seegene

What does Seegene do?
Seegene is a Korean company founded in September 2000 that focuses on molecular diagnostics, detecting disease causes by analyzing DNA and RNA from human and animal samples. Its revenue comes from manufacturing and selling diagnostic reagents, reselling reprocessed diagnostic equipment, and providing services, with its products sold through partner distributors and overseas subsidiaries in more than 100 countries and regions. Its core technology is syndromic quantitative PCR, which allows multiple pathogens and genetic targets to be tested simultaneously in a single tube, and its main product lines cover respiratory, sexually transmitted, gastrointestinal, HPV, drug-resistance and COVID-19 infection testing.
What is the market cap of Seegene?
The market capitalisation of Seegene was ₩1.5T at the close on Oct 27, 2026.
Who are the largest shareholders of Seegene?
According to the latest official filings, the largest reported holders are Cheon Jong-yun (28.78%, as of Aug 26, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.87%, as of Jul 31, 2026); iShares Core MSCI Emerging Markets ETF (0.85%, as of May 31, 2026).
When is the next earnings report from Seegene?
Korean companies rarely announce results dates in advance. Based on when Seegene filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own Seegene?
Yes. The National Pension Service held 0.64% of Seegene shares as of Dec 31, 2025.

Company profile

Seegene is a Korean company founded in September 2000 that focuses on molecular diagnostics, detecting disease causes by analyzing DNA and RNA from human and animal samples. Its revenue comes from manufacturing and selling diagnostic reagents, reselling reprocessed diagnostic equipment, and providing services, with its products sold through partner distributors and overseas subsidiaries in more than 100 countries and regions. Its core technology is syndromic quantitative PCR, which allows multiple pathogens and genetic targets to be tested simultaneously in a single tube, and its main product lines cover respiratory, sexually transmitted, gastrointestinal, HPV, drug-resistance and COVID-19 infection testing.

Written by AI from the company's latest annual report.

Korean name
씨젠
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Medical devices
CEO
천종윤, 이대훈 각자대표이사
Founded
Sep 2000
Listed
Sep 2010
Listed shares
46,734,402
Fiscal year ends
Month 12
Website
www.seegene.co.kr

Similar companies

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Seegene / 씨젠 / 096530 / KRX:096530

Source: KRX statistical information